319 established journals publish at least 20 % of their articles in Oncology. 181 of them are fully open access, and at least 2 of those charge authors nothing (diamond open access). Where open-access journals charge a fee, the median is 2 740 USD. Highest recent citation rates: CA A Cancer Journal for Clinicians, Signal Transduction and Targeted Therapy, Journal of Hematology & Oncology.
319 journals
Most relevant first: how much of a journal's work is in Oncology, how many articles it publishes and how often they are cited. Click a column to sort.
| CA A Cancer Journal for CliniciansWiley | 41 % | 59 | 227.73 | 269 | 4 330 USD |
| Journal for ImmunoTherapy of CancerBMJ | 46 % | 574 | 10.05 | 183 | 2 490 USD |
| Cancer MedicineWiley | 40 % | 1 079 | 3.85 | 122 | 4 700 USD |
| Nature CancerNature Portfolio | 35 % | 184 | 17.85 | 131 | Subscription; open access option 12 690 USD |
| BMC CancerBioMed Central | 37 % | 1 540 | 3.93 | 203 | 3 390 USD |
| The Lancet OncologyElsevier BV | 31 % | 478 | 12.43 | 521 | Subscription; open access option 7 280 USD |
| Nature Reviews Clinical OncologyNature Portfolio | 32 % | 129 | 28.78 | 286 | Subscription |
| Cancer EpidemiologyElsevier BV | 55 % | 178 | 3.04 | 92 | Subscription; open access option 3 740 USD |
| Journal of Clinical OncologyLippincott Williams & Wilkins | 39 % | 7 802 | 1.85 | 737 | Subscription |
| Cancer CellCell Press | 28 % | 198 | 34.83 | 484 | Subscription; open access option 10 400 USD |
| European Journal of CancerElsevier BV | 40 % | 897 | 3.02 | 298 | Subscription; open access option 4 270 USD |
| Journal of the National Cancer CenterElsevier BV | 41 % | 49 | 18.27 | 26 | 2 160 USD |
| Cancer Treatment ReviewsElsevier BV | 38 % | 121 | 10.37 | 205 | Subscription; open access option 4 910 USD |
| Journal of Cancer SurvivorshipSpringer Science+Business Media | 50 % | 195 | 3.21 | 107 | Subscription; open access option 4 790 USD |
| Annals of OncologyElsevier BV | 40 % | 4 305 | 1.74 | 386 | Subscription; open access option 5 080 USD |
| Signal Transduction and Targeted TherapySpringer Nature | 21 % | 422 | 49.97 | 286 | 3 790 USD |
| Trends in cancerElsevier BV | 36 % | 133 | 11.12 | 135 | Subscription; open access option 7 030 USD |
| 癌症：英文版Publisher unknown | 34 % | 138 | 13.08 | 125 | 3 080 USD |
| Cancer DiscoveryAmerican Association for Cancer Research | 31 % | 495 | 7.78 | 302 | Subscription |
| JAMA OncologyAmerican Medical Association | 31 % | 384 | 8.59 | 244 | Subscription |
| CancersMultidisciplinary Digital Publishing Institute | 25 % | 5 387 | 5.38 | 220 | 3 499 USD |
| OncoImmunologyLandes Bioscience | 39 % | 159 | 6.56 | 152 | 2 913 USD |
| British Journal of CancerSpringer Nature | 32 % | 417 | 6.92 | 345 | Subscription; open access option 5 190 USD |
| Nature reviews. CancerNature Portfolio | 29 % | 115 | 26.63 | 595 | Subscription |
| The OncologistAlphaMed Press | 40 % | 411 | 3.30 | 227 | 3 852 USD |
| Drug Resistance UpdatesElsevier BV | 35 % | 77 | 16.31 | 160 | Subscription; open access option 5 410 USD |
| International Journal of CancerWiley | 34 % | 508 | 4.47 | 328 | Subscription; open access option 5 030 USD |
| Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 33 % | 390 | 5.66 | 203 | Subscription |
| Seminars in Cancer BiologyElsevier BV | 33 % | 139 | 11.05 | 226 | Subscription; open access option 6 060 USD |
| Cell Reports MedicineElsevier BV | 26 % | 353 | 12.26 | 103 | 5 620 USD |
| Therapeutic Advances in Medical OncologySAGE Publishing | 40 % | 209 | 3.76 | 91 | 2 800 USD |
| Cancer Research CommunicationsAmerican Association for Cancer Research | 39 % | 168 | 4.74 | 32 | 2 550 USD |
| JNCI Cancer SpectrumOxford University Press | 45 % | 111 | 3.71 | 55 | 2 050 USD |
| Molecular CancerBioMed Central | 22 % | 245 | 29.52 | 284 | 5 090 USD |
| Biochimica et Biophysica Acta (BBA) - Reviews on CancerElsevier BV | 32 % | 176 | 7.61 | 206 | Subscription; open access option 5 070 USD |
| Current OncologyMultidisciplinary Digital Publishing Institute | 32 % | 663 | 3.53 | 97 | 2 654 USD |
| Cancer ControlSAGE Publishing | 41 % | 185 | 3.16 | 97 | 2 650 USD |
| Critical Reviews in Oncology/HematologyElsevier BV | 31 % | 273 | 5.94 | 181 | Subscription; open access option 4 190 USD |
| Journal of Translational MedicineBioMed Central | 23 % | 969 | 8.33 | 189 | 3 890 USD |
| Cancer Drug ResistancePublisher unknown | 42 % | 61 | 6.16 | 39 | Open access, fee unknown |
| Clinical Colorectal CancerElsevier BV | 65 % | 67 | 1.59 | 79 | Subscription; open access option 3 690 USD |
| Cancer Immunology ResearchAmerican Association for Cancer Research | 40 % | 310 | 2.54 | 171 | Subscription |
| Cancer ScienceWiley | 31 % | 406 | 4.38 | 185 | 2 600 USD |
| npj Precision OncologyNature Portfolio | 28 % | 216 | 8.98 | 81 | 4 090 USD |
| Journal of Hematology & OncologyBioMed Central | 21 % | 151 | 35.15 | 228 | 4 990 USD |
| Frontiers in OncologyFrontiers Media | 25 % | 5 383 | 2.70 | 206 | 3 801 USD |
| Journal of Experimental & Clinical Cancer ResearchBioMed Central | 22 % | 362 | 12.92 | 180 | 4 190 USD |
| Supportive Care in CancerSpringer Science+Business Media | 35 % | 868 | 2.01 | 172 | Subscription; open access option 4 690 USD |
| Future OncologyFuture Medicine | 35 % | 348 | 2.93 | 110 | Subscription |
| Cancer LettersElsevier BV | 22 % | 488 | 10.61 | 265 | Subscription; open access option 4 960 USD |
| Psycho-OncologyWiley | 36 % | 265 | 2.83 | 203 | Subscription; open access option 4 940 USD |
| JNCI Journal of the National Cancer InstituteOxford University Press | 30 % | 291 | 4.55 | 489 | Subscription; open access option 5 436 USD |
| International Journal of Colorectal DiseaseSpringer Science+Business Media | 35 % | 243 | 3.17 | 125 | Subscription; open access option 3 790 USD |
| Cancer Biology and MedicineChinese Anti-Cancer Association | 35 % | 103 | 5.38 | 69 | 1 500 USD |
| Clinical Cancer ResearchAmerican Association for Cancer Research | 30 % | 1 222 | 2.21 | 418 | Subscription |
| Cancer Immunology ImmunotherapySpringer Science+Business Media | 28 % | 290 | 5.67 | 164 | 4 590 USD |
| OncogeneSpringer Nature | 24 % | 410 | 6.72 | 423 | Subscription; open access option 5 990 USD |
| ESMO OpenElsevier BV | 34 % | 960 | 1.74 | 98 | 3 910 USD |
| Medical OncologySpringer Science+Business Media | 28 % | 347 | 4.64 | 109 | Subscription; open access option 4 290 USD |
| Journal of Cancer Research and Clinical OncologySpringer Science+Business Media | 25 % | 579 | 4.99 | 137 | 4 390 USD |
| Targeted OncologyAdis, Springer Healthcare | 36 % | 80 | 4.87 | 70 | Subscription; open access option 4 990 USD |
| Journal of CancerIvyspring International Publisher | 26 % | 426 | 4.48 | 110 | 1 337 USD |
| Translational OncologyElsevier BV | 28 % | 321 | 4.28 | 95 | 3 390 USD |
| Cancer and Metastasis ReviewsSpringer Science+Business Media | 28 % | 73 | 12.31 | 215 | Subscription; open access option 3 790 USD |
| European Journal of Oncology NursingElsevier BV | 32 % | 192 | 3.79 | 97 | Subscription; open access option 3 790 USD |
| World Journal of Gastrointestinal OncologyPublisher unknown | 36 % | 275 | 2.08 | 73 | Open access, fee unknown |
| MedCommWiley | 22 % | 263 | 10.82 | 82 | 3 500 USD |
| Experimental Hematology and OncologyBioMed Central | 24 % | 107 | 14.20 | 76 | 3 290 USD |
| Cancer Biology & TherapyTaylor & Francis | 30 % | 83 | 6.77 | 153 | 2 970 USD |
| Cancer Causes & ControlSpringer Science+Business Media | 48 % | 145 | 1.40 | 177 | Subscription; open access option 3 890 USD |
| Biomarker ResearchBioMed Central | 22 % | 124 | 15.02 | 90 | 3 890 USD |
| Journal of Thoracic OncologyElsevier BV | 31 % | 2 150 | 1.33 | 221 | Subscription; open access option 4 100 USD |
| Translational Lung Cancer ResearchAME Publishing Company | 32 % | 324 | 2.50 | 79 | Open access, fee unknown |
| MedElsevier BV | 24 % | 137 | 9.19 | 67 | Subscription; open access option 9 350 USD |
| Journal of Gastrointestinal OncologyAME Publishing Company | 36 % | 270 | 1.91 | 56 | Open access, fee unknown |
| Colorectal DiseaseWiley | 36 % | 445 | 1.57 | 130 | Subscription; open access option 4 480 USD |
| Anti-Cancer DrugsLippincott Williams & Wilkins | 37 % | 151 | 2.23 | 114 | Subscription |
| Cancer Pathogenesis and TherapyElsevier BV | 35 % | 40 | 6.34 | 21 | 1 100 USD |
| European Journal of Cancer PreventionLippincott Williams & Wilkins | 40 % | 75 | 2.72 | 102 | Subscription |
| World Journal of Clinical OncologyBaishideng Publishing Group | 36 % | 131 | 2.47 | 72 | Open access, fee unknown |
| Anticancer ResearchInternational Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts | 33 % | 647 | 1.57 | 78 | Subscription |
| Melanoma ResearchLippincott Williams & Wilkins | 46 % | 72 | 1.89 | 94 | Subscription |
| BMJ OncologyBMJ | 37 % | 38 | 5.35 | 18 | Open access, fee unknown |
| ImmunotherapyFuture Medicine | 36 % | 133 | 2.51 | 81 | Subscription |
| Investigational New DrugsSpringer Science+Business Media | 30 % | 111 | 4.28 | 114 | Subscription; open access option 4 690 USD |
| Cancer Research and TreatmentKorean Cancer Association | 32 % | 132 | 3.41 | 83 | Open access, fee unknown |
| Clinical & Translational OncologySpringer Science+Business Media | 29 % | 319 | 2.70 | 79 | Subscription; open access option 4 690 USD |
| Annals of ColoproctologyPublisher unknown | 38 % | 71 | 2.84 | 37 | 500 USD |
| BJC ReportsSpringer Science+Business Media | 36 % | 39 | 4.95 | 16 | 2 690 USD |
| Chinese Journal of Cancer ResearchAME Publishing Company | 31 % | 63 | 5.73 | 61 | Open access, fee unknown |
| Seminars in OncologyElsevier BV | 39 % | 59 | 2.90 | 148 | Subscription; open access option 3 550 USD |
| Molecular OncologyElsevier BV | 28 % | 237 | 3.44 | 145 | 4 300 USD |
| Lung CancerElsevier BV | 30 % | 619 | 1.71 | 184 | Subscription; open access option 3 390 USD |
| CancerWiley | 21 % | 605 | 4.52 | 473 | Subscription; open access option 4 790 USD |
| Asia-Pacific Journal of Oncology NursingMedknow | 32 % | 165 | 2.53 | 46 | 1 980 USD |
| Cellular OncologySpringer Nature | 29 % | 113 | 4.41 | 74 | 4 390 USD |
| Cancer Epidemiology Biomarkers & PreventionAmerican Association for Cancer Research | 38 % | 767 | 0.93 | 210 | Subscription |
| Clinical & Experimental MetastasisSpringer Science+Business Media | 33 % | 63 | 4.17 | 126 | Subscription; open access option 5 090 USD |
| BJS OpenWiley | 25 % | 212 | 4.09 | 59 | 2 881 USD |
| Current Treatment Options in OncologySpringer Science+Business Media | 25 % | 110 | 6.65 | 89 | Subscription; open access option 4 890 USD |
| Discover OncologySpringer Nature | 24 % | 767 | 2.41 | 36 | 1 690 USD |
| Journal of Gastrointestinal CancerSpringer Science+Business Media | 33 % | 158 | 2.17 | 47 | Subscription; open access option 4 190 USD |
| JCO Oncology PracticeLippincott Williams & Wilkins | 27 % | 645 | 1.92 | 61 | Subscription |
| Diseases of the Colon & RectumLippincott Williams & Wilkins | 32 % | 367 | 1.57 | 229 | Subscription |
| Cytokine & Growth Factor ReviewsElsevier BV | 23 % | 62 | 13.73 | 206 | Subscription; open access option 4 900 USD |
| Breast Cancer ResearchBioMed Central | 23 % | 164 | 5.74 | 209 | 4 190 USD |
| Exploration of Targeted Anti-tumor TherapyPublisher unknown | 28 % | 66 | 5.94 | 28 | Open access, fee unknown |
| JNCI MonographsOxford University Press | 33 % | 36 | 5.65 | 108 | Subscription |
| Current Oncology ReportsSpringer Science+Business Media | 23 % | 143 | 6.65 | 102 | Subscription; open access option 5 090 USD |
| NeoplasiaElsevier BV | 26 % | 114 | 5.13 | 158 | 3 530 USD |
| ImmunoTargets and TherapyDove Medical Press | 32 % | 39 | 5.77 | 48 | 2 320 USD |
| Clinical Lung CancerElsevier BV | 30 % | 170 | 2.60 | 90 | Subscription; open access option 3 200 USD |
| Molecular Cancer TherapeuticsAmerican Association for Cancer Research | 26 % | 478 | 2.29 | 218 | Subscription |
| JCO Global OncologyLippincott Williams & Wilkins | 28 % | 281 | 2.34 | 49 | 2 472 USD |
| American Journal of Cancer Researche-Century Publishing Corporation | 29 % | 152 | 2.85 | 18 | Subscription |
| International Journal of Clinical OncologySpringer Science+Business Media | 26 % | 222 | 2.85 | 92 | Subscription; open access option 4 590 USD |
| PancreatologyElsevier BV | 35 % | 581 | 1.03 | 111 | Subscription; open access option 4 000 USD |
| Cancer InvestigationTaylor & Francis | 36 % | 83 | 2.05 | 113 | Subscription |
| Breast Cancer Research and TreatmentSpringer Science+Business Media | 22 % | 369 | 3.53 | 220 | Subscription; open access option 4 190 USD |
| npj Breast CancerNature Portfolio | 22 % | 133 | 6.17 | 77 | 3 790 USD |
| Asian Pacific Journal of Cancer PreventionWest Asia Organization for Cancer Prevention | 26 % | 520 | 1.87 | 100 | 200 USD |
| Annals of Surgical OncologySpringer Science+Business Media | 22 % | 1 897 | 1.76 | 239 | Subscription; open access option 4 590 USD |
| Journal of Immunotherapy and Precision OncologyPublisher unknown | 39 % | 30 | 3.00 | 20 | 2 400 USD |
| JMIR CancerJMIR Publications | 28 % | 86 | 3.69 | 39 | 1 873 USD |
| American Society of Clinical Oncology Educational BookAmerican Society of Clinical Oncology | 22 % | 76 | 9.11 | 90 | Subscription |
| Cancer InnovationWiley | 32 % | 45 | 3.83 | 18 | 2 700 USD |
| In VivoStanford University Highwire Press | 27 % | 388 | 1.86 | 54 | Open access, fee unknown |
| CytokineElsevier BV | 21 % | 277 | 3.86 | 172 | Subscription; open access option 3 220 USD |
| Cancer Chemotherapy and PharmacologySpringer Science+Business Media | 30 % | 129 | 2.34 | 154 | Subscription; open access option 4 390 USD |
| Japanese Journal of Clinical OncologyOxford University Press | 27 % | 210 | 2.28 | 114 | Subscription; open access option 3 604 USD |
| Cancer Management and ResearchDove Medical Press | 25 % | 363 | 2.19 | 91 | 2 836 USD |
| Thoracic CancerWiley | 23 % | 420 | 2.33 | 67 | 3 030 USD |
| World Journal of Surgical OncologyBioMed Central | 22 % | 405 | 2.66 | 99 | 2 990 USD |
| Techniques in ColoproctologySpringer Science+Business Media | 27 % | 175 | 2.37 | 86 | Subscription; open access option 4 390 USD |
| Integrative Cancer TherapiesSAGE Publishing | 27 % | 107 | 3.07 | 91 | 2 650 USD |
| Oncology ReportsElsevier BV | 23 % | 223 | 3.05 | 131 | Subscription |
| Seminars in Oncology NursingElsevier BV | 27 % | 123 | 2.66 | 83 | Subscription; open access option 3 590 USD |
| Clinical Medicine Insights OncologySAGE Publishing | 30 % | 62 | 3.06 | 42 | 2 650 USD |
| Annals of Gastroenterological SurgeryWiley | 29 % | 139 | 2.17 | 53 | 2 350 USD |
| JTO Clinical and Research ReportsElsevier BV | 31 % | 136 | 1.74 | 33 | 2 000 USD |
| Translational Cancer ResearchAME Publishing Company | 27 % | 490 | 1.44 | 46 | Open access, fee unknown |
| Cancer NursingLippincott Williams & Wilkins | 31 % | 124 | 1.83 | 121 | Subscription |
| Lymphatic Research and BiologyMary Ann Liebert, Inc. | 41 % | 67 | 1.28 | 66 | Subscription |
| Cancer ResearchAmerican Association for Cancer Research | 28 % | 8 237 | 0.61 | 469 | Subscription |
| Molecular Therapy OncologyElsevier BV | 30 % | 64 | 2.84 | 16 | 3 900 USD |
| ESMO Gastrointestinal OncologyElsevier BV | 42 % | 46 | 1.44 | 9 | 3 170 USD |
| Colorectal CancerFuture Medicine | 66 % | 15 | 1.15 | 15 | Open access, fee unknown |
| PancreasLippincott Williams & Wilkins | 29 % | 183 | 1.69 | 140 | Subscription |
| Cancer Prevention ResearchAmerican Association for Cancer Research | 25 % | 126 | 2.98 | 131 | Subscription |
| Oncology LettersSpandidos Publishing | 21 % | 603 | 2.19 | 105 | Open access, fee unknown |
169 more journals publish in Oncology; the analysis of your paper considers all of them.
Which of these fit your paper?
Paste your title and abstract and get these journals ranked for your work, with the closest published articles as evidence. Free, and your abstract is never stored.
Journals in CWTS Journal Indicators Core or the Directory of Open Access Journals that published at least 20 articles in the last five years, mostly in English. "In this field" is the share of a journal's articles that OpenAlex classifies in Oncology. Citation rate is OpenAlex's two-year mean citedness, an open measure similar to the journal impact factor. Fees are taken from OpenAlex and DOAJ and can be out of date: always check the journal's own website before you submit.